# OnCo record paper-keynote-355-lancet-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-355-lancet-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-355-lancet-2020" ;
  schema:name "Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial"@en ;
  schema:description "Published report from the KEYNOTE-355 trial registered as NCT02819518, in The Lancet (2020), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-355-lancet-2020/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(20)32531-9>, <https://pubmed.ncbi.nlm.nih.gov/33278935/>, <https://europepmc.org/article/MED/33278935>, <https://clinicaltrials.gov/study/NCT02819518> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(20)32531-9> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Cortes J, Cescon DW, Rugo HS, et al." ;
  onco:trials <https://onco.cc/trials/keynote-355/> ;
  onco:journals <https://onco.cc/journals/lancet/> .